CLARITY PHARMA ORDINARY (CU6) Short Interest
CLARITY PHARMA ORDINARY (ASX:CU6) had 7.57% of shares reported as short positions as of 16 July 2026, representing 28,247,616 shares. CLARITY PHARMA ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4CU6 intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Clarity Pharmaceuticals
Latest CU6 news
All news- Clarity Pharmaceuticals (ASX:CU6) Shares Advance While Investors Focus on Pipeline Progress - Kalkine
googlenews
- Is Clarity Pharmaceuticals (ASX:CU6) Redefining Cancer Treatment Through Its Copper Theranostics Platform?
kalkine
- Is Clarity Pharmaceuticals’ (ASX:CU6) Copper Theranostics Pipeline Redefining Its Long-Term Oncology Strategy? - simplywall.st
googlenews
- Ceasing to be a substantial holder
asx
- Ceasing to be a substantial holder
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss CU6
Start a research thread or post the first pulse update